Premium
Additional results for ‘Sequential design approaches for bioequivalence studies with crossover designs’
Author(s) -
Montague Timothy H,
Potvin Diane,
DiLiberti Charles E.,
Hauck Walter W.,
Parr Alan F.,
Schuirmann Donald J.
Publication year - 2011
Publication title -
pharmaceutical statistics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.421
H-Index - 38
eISSN - 1539-1612
pISSN - 1539-1604
DOI - 10.1002/pst.483
Subject(s) - bioequivalence , crossover , sample size determination , statistics , crossover study , type i and type ii errors , econometrics , mathematics , computer science , medicine , pharmacology , artificial intelligence , pharmacokinetics , alternative medicine , pathology , placebo
In 2008, this group published a paper on approaches for two‐stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second‐stage sample size based on the variance estimated from the first‐stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended. Copyright © 2011 John Wiley & Sons, Ltd.